Metagenomi Therapeutics (MGX) Other Non-Current Liabilities (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Other Non-Current Liabilities data on file, last reported at $2.0 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $2.0 million, down 7.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 7.4% YoY), and the FY2025 annual result was $2.0 million, down 2.84% from the prior year.
• Other Non-Current Liabilities steadied at $2.0 million in Q1 2026 per MGX's latest filing, from $2.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $5.1 million in Q4 2023 and troughed at $1.9 million in Q3 2025.
• A 4-year average of $2.9 million and a median of $2.1 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities slumped 60.43% in 2024, then dropped 2.84% in 2025.
• A 4-year view of Other Non-Current Liabilities shows it stood at $5.1 million in 2023, then tumbled by 60.43% to $2.0 million in 2024, then declined by 2.84% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
• Business Quant data shows MGX's Other Non-Current Liabilities at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $1.9 million in Q3 2025.